Results 121 to 130 of about 3,811,568 (245)

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.

PLoS ONE, 2018
BackgroundTreatment of metastatic prostate cancer is associated with high personal and economic burden. Recently, new treatment options for castration-resistant prostate cancer became available with promising survival advantages.
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg, Judith Dams   +4 more
doaj   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Cluster headache (CH) has historically been considered a male‐dominated disorder, suggesting a role for androgens in its pathophysiology. We aimed to evaluate hormone profiles and symptoms of androgen deficiency in CH.
Willemijn C. Naber, Roemer B. Brandt, Mariël Leon Morales‐Grooters, Ronald van der Wal, Sjoerd A. A. van den Berg, Jelle J. Goeman, Antoinette Maassen van den Brink, Rolf Fronczek   +7 more
wiley   +1 more source

Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy

EMBO Molecular Medicine
A critical knowledge gap in prostate cancer research is understanding whether castration-tolerant progenitor-like cells that reside in treatment-naïve tumors play a direct role in therapy resistance and tumor progression.
Manon Baurès, Anne-Sophie Vieira Aleixo, Emeline Pacreau, Aysis Koshy, Vanessa Friedrich, Marc Diedisheim, Martin Raigel, Yichao Hua, Charles Dariane, Florence Boutillon, Lukas Kenner, Jean-Christophe Marine, Gilles Laverny, Daniel Metzger, Florian Rambow, Jacques-Emmanuel Guidotti, Vincent Goffin   +16 more
doaj   +1 more source

Evaluation of triplet therapy combined with robot‐assisted cytoreductive prostatectomy for high‐volume metastatic prostate cancer: a multicentre randomised controlled trial protocol

BJU International, Volume 138, Issue 5, Page 807-814, November 2026.
Background Prostate cancer (PCa) is the second most common cancer in men. For patients with high‐volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended.
Xiangwei Yang, Zhuobin He, Jian Chen, Hanqi Lei, Binyuan Yan, Linze Chen, Hong Liu, Jun Pang   +7 more
wiley   +1 more source

Abiraterone in the treatment of metastatic castration-resistant prostate cancer

, 2014
Elahe A Mostaghel Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Abstract: Androgen deprivation therapy remains the single most effective treatment for the initial therapy of advanced prostate cancer, but is ...
Mostaghel EA
core  

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

PURPOSE: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance is inevitable ...
Bertan, C, Coleman, I, Crespo, M, Jones, K, Sharp, A, Rekowski, J, Chessum, N, Li, D, Swain, A, Carreira, S, de Bono, JS, Roumeliotis, TI, Cheeseman, M, Ning, J, Gurel, B, Neeb, AJ, Jiménez Vacas, J, Gil, VS, Weigl, F, Zeng, W, Choudhary, J, Workman, P, Liodaki, K, Yuan, W, Bhamra, A, Pasqua, E, Banerji, U, Ferreira, A, Nelson, PS, Riisnaes, R, Bogdan, D, Buroni, L, Miranda, S, Tunariu, N, Te Poele, R, Powers, M, Figueiredo, I, Clarke, P, Welti, J, Bernett, I   +39 more
core   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, Volume 600, Issue 19, Page 2850-2873, October 2026.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!

International Journal of Biological Sciences, 2011
Prostate cancer is the second leading cause of cancer-related death in American men. Although most prostate cancers are initially androgen-dependent and respond to androgen ablation therapy, majority of them eventually relapse and progress into incurable
Zhiyong Guo, Yun Qiu
doaj